COMMUNIQUÉS West-GlobeNewswire

Informations relatives au nombre total de droits de vote et d’actions composant le capital

03/04/2025 - 08:00

Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 3 avril 2025 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement [...]

Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

03/04/2025 - 07:00

Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under [...]

Communiqué de presse : Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de deux maladies rares contre lesquelles il n’existe aucun médicament approuvé

03/04/2025 - 07:00

Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de deux maladies rares contre lesquelles il n’existe aucun médicament approuvé Désignation accordée pour l’anémie [...]

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

03/04/2025 - 07:00

Leiden, the Netherlands, April 3, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2024 (the “ [...]

Veteran Banker Joins Avextra’s Supervisory Board

03/04/2025 - 07:00

News Release Dr. Stefan Jentzsch, Partner at the global investment firm Perella Weinberg Partners has been appointed to Avextra’s Supervisory Board, bringing decades of experience in corporate finance, M&A, and [...]

FibroBiologics annonce des progrès scientifiques suite à la confirmation des résultats relatifs à la réparation de tissus cérébraux

03/04/2025 - 04:33

HOUSTON, 03 avr. 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq : FBLG), ou « FibroBiologics », une société de biotechnologie au stade clinique détenant plus de 240 brevets délivrés et en instance portant sur le [...]

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

03/04/2025 - 02:13

Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program 1 [...]

RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance

03/04/2025 - 02:00

ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

03/04/2025 - 01:15

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its plans to meet with the United [...]

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

02/04/2025 - 23:00

AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF [...]

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02/04/2025 - 22:30

SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

02/04/2025 - 22:15

Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancer [...]

NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers de l’exercice 2024

02/04/2025 - 22:15

Le programme de développement global de JNJ-1900 (NBTXR3) progresse comme prévu, avec l’opportunité d’adresser l’un des plus grands marchés inexploités en oncologie grâce aux programmes les plus avancés dans le cancer [...]

Range Impact Announces Major Land Acquisition in West Virginia

02/04/2025 - 22:15

CLEVELAND, OHIO, April 02, 2025 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTCQB: RNGE) (“Range Impact” or the “Company”), a public company dedicated to acquiring, reclaiming and repurposing distressed coal mines [...]

eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO

02/04/2025 - 22:10

Expanded leadership team as eXoZymes ramps up commercial growth Damien Perriman brings more than two decades of experience in successfully developing and commercializing novel biotechnologies Focus on developing [...]

ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®

02/04/2025 - 22:05

PORTLAND, Maine, April 02, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]

Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025

02/04/2025 - 22:05

SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2025 on Wednesday, April 23, 2025, [...]

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

02/04/2025 - 22:05

SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025. [...]

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02/04/2025 - 22:05

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight [...]